The Binding Site’s Post

Unlike some other cancers, Myeloma can present with various and vague indications. Multiple Myeloma most frequently affects people over 60 years of age and common presenting symptoms can often be associated with the natural aging process. In this clip, Professor Andrew Spencer provides insight into some common symptoms to help Primary Care Providers recognize the signs of Multiple Myeloma, helping them in effective early diagnoses. Learn more about Multiple Myeloma diagnosis criteria for primary care providers: https://hubs.li/Q02TWM6t0 #MultipleMyeloma #Diagnosis

The journey towards diagnosing Multiple Myeloma, a cancer of the bone marrow, can often be complex, primarily due to the non-specific and heterogenous presenting symptoms of this insidious disease. We had the privilege of sitting down with Professor Andrew Spencer, Head of Malignant Haematology, Stem Cell Transplantation and Head of Myeloma Research at The Alfred Hospital, Australia to discuss the pivotal role of primary care providers in myeloma detection and precursor management. Stay tuned for more insights on early detection and management. #MultipleMyeloma #Diagnosis

This year we will be attending the APFCB Congress in Sydney. Come and speak to our team to hear more about our latest innovation for monoclonal assessment, the EXENT® System! Register for a live demonstration: https://hubs.li/Q02Td4WZ0 #Innovation #Multiplemyeloma #EXENTSystem

Next week we are flying to Marseille to attend the 21st Biennial Meeting of The European Society for Immunodeficiencies (ESID), 16th - 19th October, an event that will bring together the global PID community. Come and talk to us. We will be at booth 17A. #ESID2024

Today, we are at The NEC, Birmingham for Best Practice, an event that provides world-class training for primary care and healthcare practitioners. Come and chat with us at Booth F140 Dr. Dean Smith, Consultant Haematologist and Myeloma lead at Nottingham University Hospitals will be leading a workshop on 'Recognising and investigating suspected Myeloma' at Best Practice Workshop Theatre at 14:30 – 15:00.

This week, we are pleased to celebrate Customer Service Week and shine a spotlight on our team here at The Binding Site, part of Thermo Fisher Scientific. Our colleagues are dedicated to providing exceptional service, from our frontline teams to those in supporting roles. Each individual plays a vital part in solidifying our position as a trusted partner in special protein diagnostics, delivering cutting-edge diagnostic solutions that empower healthcare professionals across the globe in diagnosing and monitoring blood cancers and immune systems disorders. This commitment is central to our mission to enable our customers to make the world healthier, cleaner, and safer.

Thank you to everyone who participated in our recent poll! The correct answer is 19% — approximately 19% of newly diagnosed blood cancer cases in the United States are myeloma. Early detection is crucial, and primary care providers play a pivotal role in identifying the symptoms of this serious disease. Stay informed, and help us spread awareness about the importance of recognizing myeloma early. Learn more here: https://lnkd.in/emKbYPnn #kNOwMyeloma #EarlyDetectionMatters #MyelomaAwareness

In an era of highly effective treatments inducing rapid and deep responses, new solutions are needed to improve Multiple Myeloma assessment. With just a blood sample, MALDI-ToF Mass Spectrometry can provide clinicians with a greater level of confidence and understanding of their patient’s disease. Watch this video from Dr. Lauren Campbell on the use of Mass Spectrometry when monitoring a patient’s treatment journey.

What if... You could increase clarity throughout your patient treatment journey with MALDI-ToF mass spectrometry? We will be sharing insights from Dr. Lauren Campbell on the use of Mass Spectrometry tomorrow.

Today is European Myeloma Day, and we are proud to stand with Myeloma Patients Europe (MPE) in raising awareness about Multiple Myeloma, which is the second most common blood cancer. Although it is one of the most common blood cancers, Multiple Myeloma may not be a familiar term to you. We partnered with Macmillan Cancer Support, British Skin Foundation and Cancer Research UK (CRUK) to highlight the importance of effective diagnosis and monitoring of Multiple Myeloma, in this video from ITN. Find more information about European Myeloma Day here: https://hubs.li/Q02R2VXc0 #EuropeanMyelomaDay